…
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 627.80M | 413.10M | 271.90M | 440.30M | 242.30M |
| Net income | 500.30M | 329.90M | 216.80M | 349.50M | 193.80M |
| Selling general administrative | 86.80M | 81.70M | 74.80M | 279.10M | 238.90M |
| Selling and marketing expenses | 289.50M | 278.10M | 224.80M | - | - |
| Gross profit | 1213.00M | 946.40M | 657.70M | 849.00M | 593.50M |
| Reconciled depreciation | 56.70M | 92.80M | 51.50M | 47.50M | 45.80M |
| Ebit | 624.77M | 420.70M | 277.10M | 438.90M | 240.30M |
| Ebitda | 681.04M | 513.50M | 328.60M | 489.30M | 289.10M |
| Depreciation and amortization | 56.28M | 92.80M | 51.50M | - | - |
| Operating income | 629.00M | 416.60M | 274.90M | 436.40M | 237.70M |
| Other operating expenses | 1257.90M | 1125.80M | 914.70M | 4.50M | 2.80M |
| Interest expense | 8.20M | 7.60M | 5.20M | 1.50M | 1.00M |
| Tax provision | 127.50M | 83.20M | 55.10M | 90.80M | 48.50M |
| Interest income | 4.60M | 4.60M | 2.90M | 1.00M | 0.10M |
| Net interest income | -4.00M | -3.80M | -2.80M | -0.80M | -1.20M |
| Income tax expense | 127.50M | 83.20M | 55.10M | 90.80M | 48.50M |
| Total revenue | 1889.50M | 1542.40M | 1189.60M | 1340.70M | 1041.00M |
| Total operating expenses | 581.40M | 529.80M | 382.80M | 904.30M | 803.30M |
| Cost of revenue | 676.50M | 596.00M | 531.90M | 491.70M | 447.50M |
| Total other income expense net | -1.20M | -3.50M | -3.00M | - | - |
| Net income from continuing ops | 500.30M | 329.90M | 216.80M | 349.50M | 193.80M |
| Net income applicable to common shares | - | - | - | 349.50M | 193.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2009.90M | 1629.10M | 1438.60M | 1503.60M | 1114.00M |
| Intangible assets | 100.30M | 87.90M | 112.90M | 103.70M | 55.50M |
| Other current assets | 0.90M | 15.60M | 55.60M | 0.20M | 0.20M |
| Total liab | 725.40M | 624.10M | 548.50M | 595.50M | 366.10M |
| Total stockholder equity | 1284.50M | 1005.00M | 890.10M | 908.10M | 747.90M |
| Other current liab | 194.80M | 147.00M | 120.20M | 31.80M | 36.20M |
| Common stock | 92.20M | 92.20M | 92.20M | 92.20M | 92.20M |
| Capital stock | 92.20M | 92.20M | 92.20M | 92.20M | 92.20M |
| Retained earnings | 1192.60M | 922.10M | 813.30M | 822.90M | 680.80M |
| Other liab | - | - | - | 123.30M | 52.20M |
| Good will | 87.20M | 87.20M | 87.20M | 87.20M | 13.50M |
| Other assets | - | 0.10M | -0.30M | 121.40M | 53.30M |
| Cash | 160.90M | 205.60M | 106.70M | 332.60M | 216.70M |
| Total current liabilities | 560.30M | 273.70M | 264.80M | 275.40M | 209.20M |
| Current deferred revenue | - | - | 1.10M | - | - |
| Net debt | 144.39M | 121.70M | 93.30M | - | - |
| Short term debt | 190.00M | 30.10M | 29.00M | - | - |
| Short long term debt | 184.80M | 25.70M | 25.70M | 13.80M | - |
| Short long term debt total | 305.29M | 327.30M | 200.00M | - | - |
| Other stockholder equity | -0.30M | -24.80M | -12.10M | 27.80M | -6.90M |
| Property plant equipment | - | - | - | 312.20M | 301.10M |
| Total current assets | 1344.40M | 1016.20M | 825.30M | 878.70M | 690.30M |
| Net tangible assets | - | - | - | 717.10M | 678.90M |
| Short term investments | - | - | -7.80M | - | - |
| Net receivables | 726.30M | 376.40M | 296.80M | 196.70M | 187.50M |
| Long term debt | 105.90M | 290.70M | 166.30M | 192.00M | 100.00M |
| Inventory | 456.30M | 418.60M | 362.20M | 315.60M | 265.20M |
| Accounts payable | 123.50M | 87.10M | 102.30M | 114.40M | 89.60M |
| Accumulated other comprehensive income | - | 15.50M | 12.60M | - | - |
| Non currrent assets other | 15.20M | 11.80M | 76.30M | - | -0.20M |
| Non current assets total | 665.50M | 612.80M | 613.30M | 624.90M | 423.70M |
| Capital lease obligations | 14.60M | 10.90M | 8.10M | 8.10M | 8.50M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -85.20M | -115.70M | -154.30M | -80.20M |
| Change to liabilities | - | - | - | -31.90M | -7.70M |
| Total cashflows from investing activities | -98.60M | -85.20M | -108.40M | -154.30M | -80.20M |
| Net borrowings | -25.70M | 124.30M | -13.90M | 69.40M | -3.60M |
| Total cash from financing activities | -263.60M | -108.80M | -243.20M | -159.80M | -214.80M |
| Net income | 500.30M | 413.10M | 216.80M | 349.50M | 193.80M |
| Change in cash | -44.70M | 98.90M | -225.90M | 115.90M | -77.70M |
| Begin period cash flow | 205.60M | 106.70M | 332.60M | 216.70M | 294.40M |
| End period cash flow | 160.90M | 205.60M | 106.70M | 332.60M | 216.70M |
| Total cash from operating activities | 316.80M | 293.40M | 119.00M | 434.40M | 215.70M |
| Depreciation | 56.70M | 92.80M | 51.50M | 47.50M | 45.20M |
| Other cashflows from investing activities | -21.20M | -22.90M | -42.70M | -0.10M | 0.10M |
| Dividends paid | 231.10M | 228.00M | 224.90M | 211.20M | 211.20M |
| Change to inventory | -38.00M | -56.40M | -47.90M | -4.10M | -6.90M |
| Change to account receivables | -336.50M | -35.80M | -89.00M | 11.00M | -21.70M |
| Sale purchase of stock | - | 0.00M | 0.00M | -17.90M | - |
| Other cashflows from financing activities | -6.80M | -5.10M | 0.10M | -0.10M | -0.10M |
| Change to netincome | - | - | - | 62.40M | 13.00M |
| Capital expenditures | 97.60M | 86.90M | 116.80M | 56.50M | 47.00M |
| Change in working capital | -297.50M | -71.30M | -144.80M | -25.00M | -36.30M |
| Stock based compensation | - | - | 12.20M | - | - |
| Other non cash items | 57.30M | -48.40M | -16.70M | 62.90M | 2.40M |
| Free cash flow | 219.20M | 206.50M | 2.20M | 361.30M | 130.70M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ORINF Orion Oyj |
- -% |
115.60 | 19.02 | 27.78 | 6.29 | 8.80 | 5.42 | 14.97 |
| LLY Eli Lilly and Company |
-21.29 1.50% |
1394.26 | 38.16 | 24.15 | 12.72 | 29.95 | 13.31 | 25.43 |
| JNJ Johnson & Johnson |
-3.08 1.10% |
275.62 | 30.96 | 20.79 | 6.58 | 7.55 | 6.84 | 19.73 |
| ABBV AbbVie Inc |
-4.77 1.63% |
288.05 | 74.10 | 16.21 | 7.22 | 50.46 | 8.18 | 27.04 |
| RHHVF Roche Holding AG Participation |
7.51 1.59% |
480.00 | 24.16 | 16.53 | 5.71 | 8.88 | 4.94 | 14.76 |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
| Name | Title | Year Born |
|---|---|---|
| Mr. Timo Lappalainen | Advisor | 1962 |
| Dr. Liisa Hurme | Pres, CEO & Chairman of Exec. Management Board | 1967 |
| Mr. Jari Karlson M.Sc., M.Sc. (Econ.) | CFO, Sr. VP of Animal Health & Member of the Exec. Management Board | 1961 |
| Mr. Olli Huotari Ll.M. | Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board | 1966 |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board | 1966 |
| Ms. Virve Laitinen M.Sc. (Tech.), MBA | Sr. VP of Specialty Products & Member of Exec. Management Board | 1972 |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP for R&D and Member of Exec. Management Board | 1962 |
| Mr. Juhani Kankaanpaa | Sr. VP of Global Operations & Member of Exec. Management Board | NA |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer | NA |
| Ms. Terhi Ormio | VP of Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.